Ridgeline Discovery GmbH

None   Welcome to this week's (and last week's) Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Galapagos sees 2 more C-suite members leave the island Galapagos Gilead Sciences-backed Galapagos went through a 2022 pipeline pivot without a chief scientific officer; now, it starts 2023 down two additional C-suite members. The company reported in late December that Chief Medical Officer Walid Abi-Saab, M.D., has decided to leave the company in addition to Chief Business Officer André Hoekema. Abi-Saab is staying on through May 2023 while the company finds a replacement.  The departure of Abi-Saab adds significant pressure to CEO Paul Stoeffels, who is rounding out his first year on the job, a bumpy tenure that’s been defined by new beginnings. Over the course of the year, the company essentially rebuilt its pipeline, ditching programs ranging from pulmonary fibrosis to inflammatory diseases for a suite of cell therapies sourced from acquisitions. It’s quite the change from the company that nabbed a $5 billion deal from Gilead to boost the larger pharma's inflammatory ambitions. As part of the clinical transition, Galapagos laid off more than 200 staffers.  With 2023 upon us, the company is hoping to build momentum on its newfound goals, specifically launching a differentiated CAR-T therapy every year for the next three years. Release  Moderna plucks another former Merck leader to spearhead commercial work Moderna  Almost nine months after Merck’s chief marketing officer Arpa Garay bolted to lead commercial work at Moderna, another top Merck leader is joining the Cambridge-based mRNA output. Moderna announced that Chantal Friebertshäuser would be joining to lead commercial efforts in Europe, Canada and the Middle East. She previously worked out of Merck & Co.’s Germany office as a human health senior vice president and managing director.  Friebertshäuser’s departure marks the end of a 10-year tenure at Merck & Co. that began in 2012 as a business director for primary care. She was promoted to managing director of Austria in 2015 before rising to global brand leader. Now at Moderna, her reach stretches beyond just one country’s borders.  Her arrival comes as Moderna is continuing to sell its COVID vaccine around the world, signing agreements with national governments while entering the private market in the U.S. But Moderna is also bracing to add additional products to its commercial portfolio, including an RSV vaccine slated to read out in the first quarter of 2023 and a cytomegalovirus vaccine that’s in a phase 3 study of its own. Fierce Pharma Zymeworks’ CMO heads for the exits amid management reconfiguration Zymeworks  Following “unprecedented” phase 2 results of the company’s biliary tract cancer med, zanidatamab, Zymeworks is rejigging its executive team to directly reflect its top-heavy priorities. As if its pipeline was a classroom with both honors and non-honors students, Zymeworks is splitting its management team in half, with one focusing on zanidatamab and the other focused on, well, everything else. As a part of the executive changes, chief medical officer Neil Josephson, M.D., is headed for the exits.  The changes reflect the weight that zanidatamab has on Zymeworks’ greater finances, after positive phase 2 data led Jazz Pharmaceuticals to pay $325 million to opt into rights for the drug in key markets including the U.S., Europe and Japan. Zymeworks has also handed rights of the med over to Beigene in key ex-Japan Asia markets, Australia and New Zealand. Leading up the zanidatamab wing of the organization is President and COO Neil Klompas. The head of the early-stage development arm will be newly appointed SVP of early development Jeffrey Smith.  The managerial overhaul comes after a tumultuous year for Zymeworks, which included a shareholder battle and layoffs. But CEO Kenneth Galbright has white-knuckled through the ups and downs, with the commercial promised land potentially on the horizon. Release Biogen separates R&D, seeks head of research Biogen The neurological disease biotech has decided it will separate its research and development into two distinct operations, both of which will report directly to CEO Christopher Viehbacher. As the company searches for a head of research, Priya Singhal, M.D., Biogen’s current head of global safety and regulatory sciences and interim head of R&D, will step into the new role of EVP and head of development.  Singhal joined Biogen in 2012 as VP of clinical trials and benefit-risk management before leaving in 2018 to head up R&D at Zafgen, then joined Biogen once again in 2020. Release > Texas-based Taysha Gene Therapies has appointed its chair Sean Nolan to lead as CEO following the resignation of RA Session II, who will continue to serve on the company’s board. Additionally, Sukumar (Suku) Nagendran, M.D., a director on the biotech’s board, has been appointed president and head of R&D. Release > Mohamed Zaki, M.D., Ph.D., has left his role as AbbVie’s VP and global head of oncology development to join ADC Therapeutics as its new CMO. Zaki succeeds Joseph Camardo, M.D., who is stepping down to pursue other opportunities. Release > Joseph Vittiglio has joined bluebird bio from Finch Therapeutics, stepping into the same roles of chief business and legal officer. Release > While announcing a phase 2 trial success, Renibus Therapeutics has also unveiled a double-dose of CEOs. Renibus used the readout to also reveal that Jeff Keyser, Ph.D., co-founder, president and current chief operating officer, will be joining Frank Stonebanks as co-CEO. Fierce Biotech > CRISPR Therapeutics has appointed Alex Harding, M.D., to serve as SVP and head of business development. Harding joins the gene editing company from Remix Therapeutics, and also helped start new biotechs—including Remix—when he previously worked at Atlas Venture. Release > Remix Therapeutics has tapped Agios’ Chris Bowden, M.D., to lead clinical development as chief medical officer. Before serving as Agios’ CMO and strategic adviser, Bowden has held roles at Roche’s Genentech, Bristol-Myers Squibb, Pharmacia Corp. and Janssen Pharmaceutical. Release > Zachary Roberts, M.D., Ph.D., who has previously held clinical leadership roles at Instil Bio and Kite Pharma, is joining Allogene’s team as EVP of R&D. Roberts will assume the responsibilities of Rafael Amado, M.D., who was Allogene’s EVP, head of R&D and chief medical officer for more than three years. Amado has headed to China and U.S.-based Zai Lab, where he has taken up the role of president and head of global oncology R&D. Release > Reset Pharmaceuticals is pressing restart, with a new CEO and president to kick off the new year. Innes Meldrum is taking over for Jan-Anders Karlsson, Ph.D., a founder of Reset Pharma. Meldrum most recently served as SVP and chief commercial officer for Otsuka Pharmaceuticals North America and has past work experience at Orexo and Novartis as well. Release > Pheast Therapeutics has ended its search for a permanent CEO, tapping Jacopo Leonardi to lead the oncology biotech. Since Pheast’s inception in 2020, Amira Barkal, M.D., Ph.D., principal founder and founding CEO, has led as interim CEO. Barkal will now serve as chief development officer while Leonardi takes the seat at the head of the table. The new CEO also serves as a venture adviser to Agent Capital and has held roles at Horizon Therapeutics, Baxalta, Baxter Healthcare, Eli Lilly and Johnson & Johnson. Release > Oncopeptides has appointed Monica Shaw to helm the Swedish biotech as CEO. She replaces Jakob Lindberg, who has been in charge since November 2021 and will assume his previous position as chief scientific officer. Before Oncopeptides, Shaw held leadership roles at GSK, LEO Pharma and Novartis. Release > At the top of the new year, Aerami Therapeutics welcomed Lisa Yañez as its new CEO upon Steve Thornton’s retirement. Yañez joined the company in 2022 as chief operating officer and has over 25 years of leadership experience across Merck, Genentech, GSK, United Therapeutics and Acceleron Pharma. Release > Harvard spinout Rejuvenate Bio has appointed Deborah Ascheim, M.D., to serve as the company’s first chief medical officer. Before Rejuvenate, Ascheim held the same position at StrideBio. She’s also the former president of d2a Ltd., former CMO for Capricor Therapeutics, and holds more than two decades of experience as a heart failure cardiologist and clinical trialist. Release > Otsuka Medical Devices’ ReCor Medical kicked off the New Year with the appointment of Lara Barghout as president and CEO. She’s taking the reins from Andrew Weiss, who has led ReCor since early 2013. Barghout joins ReCor from Siemens Healthineers, where she spent four years as SVP of the North American division of advanced therapies. Prior to Siemens, she was at Terumo Cardiovascular for nearly two decades. Fierce Biotech > Fulcrum Therapeutics CEO Bryan Stuart has left the clinical-stage company to pursue other opportunities. In his place steps Robert Gould, Ph.D., former president and founding CEO of Fulcrum, while the board seeks a permanent replacement. Release  > Novadip Biosciences has appointed Judy Ashworth, M.D., as chief medical officer. Ashworth is also currently SVP at Pinney Associates and the CMO for Harm Reduction Therapeutics. She will guide Novadip’s clinical programs, including an upcoming Type C meeting with the FDA regarding the next development step for NVD-003, an autologous therapy aimed to help save limbs and restore mobility​ in patients with a rare pediatric bone condition. Release > ADC biotech ImmunoGen has tapped Michael Vasconcelles, M.D., to serve as EVP of R&D and medical affairs. Most recently, Vasconcelles was senior advisor for life sciences at Frazier Healthcare Partners. He has also worked in a range of positions across Flatiron Health, Unum Therapeutics, Takeda/Millennium, Genzyme and Sanofi. Release > Venatorx Pharmaceuticals Chief Medical Officer Timothy Henkel, M.D., Ph.D., has announced his retirement from the infectious disease therapy company. Henkel had held the CMO position since 2015. Release > Marc Semigran, M.D., is joining Edgewise Therapeutics to serve as chief development officer. He most recently served as chief medical officer at Renovacor through its acquisition by Rocket Pharmaceuticals. Release > Francois Lebel, M.D., has stepped down from his spot as Spectrum Pharmaceuticals’ EVP and chief medical officer. The company’s clinical development operations is currently being led by Spectrum’s VP of clinical development Shanta Chawla. Release > Replimune Group is mixing up its leadership team, shifting Chief Commercial Officer Sushil Patel, Ph.D., to the newly created position of chief strategy officer and appointing Christopher Sarchi as chief operating officer. The incoming Sarchi brings along more than 28 years of oncology leadership experience, including head of commercial U.S. oncology at Sanofi positions at Boehringer Ingelheim, Roche’s Genentech and GSK. Release > Alentis Therapeutics has appointed Luigi Manenti, M.D., to serve as the Swiss biotech’s chief medical officer. Manenti most recently held the same position at HiFiBiO Therapeutics and has past experience at Novartis and Roche. Release > Massachusetts-based Apellis Pharmaceuticals has tapped Caroline Baumal, M.D., to serve as chief medical officer in place of current CMO Federico Grossi, M.D., Ph.D., who will remain at Apellis until Feb. 28 to help with the transition. Baumal is an ophthalmology professor at Tufts Medical Center in Boston and has been involved with research and clinical trials investigating new therapies for retinal diseases. Release > Abintus Bio, a genetic medicines biotech, has welcomed Lior Nissim, Ph.D., aboard. Nissim, who pioneered the first engineered gene circuit for precise targeting of cancer cells, will serve as Abintus’ head of synthetic biology. Release > Charm Therapeutics is expanding its team with the addition of five new leaders. Ross Pettit is joining from H3 Biomedicine and will serve as Charm’s chief operating officer, while Sarah Skerratt is joining from Merck Sharp & Dohme to take up the position as SVP and head of drug discovery. Daniel Rohle, joining from Biology at Ridgeline Discovery, will become VP and head of cancer biology, while Andrew Doré, who previously worked at Sosei Heptares, will serve as VP and head of structural sciences. Sergey Bartunov will serve as Charm’s director of AI, and joins after working on projects for Alphabet’s Deep Mind and being involved with several AI-driven startups. Release > BrainStorm Cell Therapeutics has promoted Stacy Lindborg, Ph.D., from her position as EVP and chief development officer to co-CEO. She will work alongside Chaim Lebovits, who will maintain his position as president and CEO. Before joining BrainStorm in 2020, Lindborg held senior leadership roles at Eli Lilly and Biogen. Additionally, Ralph Kern, M.D., is set to retire from his current role as president and chief medical officer. Release > Biotech innovation company Aditxt has formed a U.S.-based subsidiary called Adimune that will be helmed by Joachim-Friedrich Kapp, M.D., Ph.D. Kapp is the former president of the Therapeutics Business Unit at multinational pharmaceutical company Schering AG. Release > Eterna Therapeutics has tapped Matt Angel, Ph.D., to lead as CEO and president. Angel has served as the company’s interim CEO since May 2022 and also serves as Factor Bioscience’s co-founder, chair and CEO as well as co-founder and scientific advisory board chair for Exacis Biotherapeutics. Release > CRO Emmes has tapped Matt Honan to fill its newly created position of VP and global head of corporate development. Prior to Emmes, Honan most recently served as senior director of M&A and business development at Quest Diagnostics. Release

PRESS RELEASE CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities. Effective immediately, CHARM has appointed Ross Pettit as Chief Operating Officer, Sarah Skerratt as Senior Vice President, Head of Drug Discovery, Daniel Rohle as Vice President, Head of Cancer Biology, Andrew Doré as Vice President, Head of Structural Sciences, with a focus on drug discovery and development and Sergey Bartunov as Director, AI. These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development. CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures. Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership. With world-class 3D deep learning and structure-based drug design technology, the CHARM team is well positioned to execute on the pipeline.” Laksh Aithani, co-founder, Chief Executive Officer and Board Member of CHARM Therapeutics, added: “I’m really happy to welcome Ross, Sarah, Dan, Andy and Sergey to the CHARM family. Their expertise will coalesce to help us build out a robust R&D function. This enables us to start to translate the output of our proprietary 3D deep learning technology, which focuses on predicting the co-crystal structure of a protein-ligand complex, into moving targets towards development.” Strength of new discovery and development talent Ross Pettit joins as Chief Operating Officer. Ross has over 30 years of extensive drug development experience in the biopharmaceutical industry across clinical operations, program management, data management, regulatory affairs and medical affairs. He joins CHARM from H3 Biomedicine, where he worked as Deputy President, holding leadership responsibilities over all business operations and leading the exclusive out-license of H3 Biomedicine’s splicing modulator to Roivant Sciences. Ross previously served in senior roles at Beigene Pharmaceuticals, AMAG Pharmaceuticals and ARIAD Pharmaceuticals. He holds an MBA in Healthcare management. As Senior Vice President, Head of Drug Discovery, Sarah Skerratt brings expertise across multiple areas of drug discovery that include medicinal chemistry, pharmacology, pharmacokinetics, toxicology, and pharmaceutical sciences, with senior experience ranging from biotech to large pharma. Sarah joins CHARM from Merck Sharp & Dohme, where she worked as Head of Preclinical Sciences at the London site, responsible for building and leading a multidisciplinary preclinical team. She has also served in senior positions at Vertex and Convergence/Biogen and spent many years at Pfizer Inc (2004-2016), where she held numerous roles with a strong track record in drug development. Sarah is an organic chemist by training, conducting her Ph.D. at the University of Nottingham before undertaking postdoctoral studies at Stanford University as a visiting Fulbright Scholar. Daniel Rohle joins CHARM as Vice President, Head of Cancer Biology. Daniel Rohle has strong experience in oncology drug discovery and translational research culminating in publications in top tier journals, including Nature and Science. His most recent position before joining CHARM was as Vice President, Biology at Ridgeline Discovery, where he led the basic biology and assay development group for biotech companies that Ridgeline Discovery was helping to build. He previously worked at Hoffman La Roche as a member of the leadership team in the Molecular Targeted Therapeutics group, and at GSK as an investigator in the Tumor Signalling DPU. Daniel holds a PhD in Pharmacology from the Weill Cornell Graduate School of Medical Sciences, which he obtained whilst working at Memorial Sloan Kettering in a collaboration with Agios Pharmaceuticals. As Vice President, Head of Structural Sciences, Andrew Doré heads CHARM’s interdisciplinary structural sciences group and brings senior experience with global pharmaceutical companies. Previously, Andrew spent 12 years as Director and Head of Crystallography at Sosei Heptares UK, founding and establishing the now world-renowned Crystallography and structural biology department with resultant landmark publications in Nature, Science and Cell. Prior to this he completed his postdoctoral studies at the Institute of Cancer Research in London. Andrew obtained his DPhil in Protein Crystallography from the University of Cambridge. As Director of AI, Sergey Bartunov brings more than 10 years of expertise in artificial intelligence and machine learning more specifically in Bayesian machine learning and deep learning. Prior to joining CHARM, Sergey worked on cutting edge AI projects at Alphabet’s Deep Mind and was a senior member of the teaching staff at the National Research University Higher School of Economics in Moscow, Russia. He was also involved with a number of AI-driven start-ups. He holds an MSc PhD from Moscow State University. ENDS For further information, please contact: CHARM Therapeutics Laksh Aithani, Chief Executive Officer Phone +44 7933 185425 laksh@charmtx.com Consilium Strategic Communications Amber Fennell /Jessica Hodgson / Chris Gardner Phone: 44 (0)20 3709 5700 charm@consilium-comms.com About CHARM Therapeutics CHARM Therapeutics is a 3D deep-learning research Company discovering and developing transformational medicines. Founded on 3D deep learning inspired by the breakthroughs of co-founder David Baker, CHARM Therapeutics has developed a proprietary technology based on the first rapid, accurate protein/ligand co-folding algorithm. The Company’s goal is to use these insights to address challenging targets in cancer and other disease areas and discover and develop new drugs against these targets. CHARM Therapeutics is Chaired by Gary Glick, founder of IFM Therapeutics, Scorpion Therapeutics and Odyssey Therapeutics. Laksh Aithani, a former machine learning engineer at Exscientia and start-up founder, is co-founder and Chief Executive Officer. London-based CHARM Therapeutics has raised $50 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology. It supported by high quality international investors including Orbimed, F-Prime, General Catalyst, Khosla Ventures, Axial and Braavos. For more information, please visit: www.charmtx.com